Terns Pharmaceuticals (NASDAQ:TERN) Earns Outperform Rating from BMO Capital Markets
BMO Capital Markets reaffirmed their outperform rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a report released on Monday morning, Benzinga reports. The brokerage currently has a $26.00 price target on the stock, up from their previous price target of $19.00. Separately, JMP Securities upped their target price on shares of Terns […]
20 Sep 03:40 · The Cerbat Gem